BioCentury | Jan 31, 2000
Clinical News

North American Vaccine preclinical data

...to market the Hib vaccine, which is in preclinical development, in combination with its marketed Certiva...
BioCentury | Nov 22, 1999
Strategy

North American Vaccine pipeline

...North American Vaccine pipeline Product Indication Status Partner Acellular pertussis vaccines Certiva (DTaP) Prevent diphtheria, tetanus...
BioCentury | Nov 22, 1999
Strategy

What NVX adds to Baxter

...little more could go wrong for the company, which had lost marketing partners for its Certiva...
...for a way out of the investment (see BioCentury, Aug. 30). NVX (Columbia, Md.) markets Certiva...
...product in October (see BioCentury, Oct. 25). NVX and Baxter will consider whether to repartner Certiva...
BioCentury | Nov 1, 1999
Clinical News

Haemophilus influenzae type b (Hib) conjugate vaccine: Began Phase I testing

...Late next year, NVX expects to begin testing the Hib vaccine in combination with its Certiva...
BioCentury | Oct 25, 1999
Strategy

North American Vaccine: 4th strike

...When its Certiva diphtheria, tetanus and acellular pertussis (DTaP) vaccine received FDA approval last year, North...
...vaccines. But earlier this month, Abbott (Abbott Park, Ill.) terminated its 1996 agreement to market Certiva...
...the private market, which include re-partnering Certiva. "Abbott had no problems with safety or with Certiva...
BioCentury | Oct 25, 1999
Company News

North American Vaccine, Chiron Behring GmbH & Co. sales and marketing update

...NVX said that Chiron Behring is seeking to terminate its agreement to market NVX's Certiva DTaP...
BioCentury | Oct 11, 1999
Finance

Roche's round trip

...$0.687 to $6.938 on the week after Abbott terminated its 1996 agreement to market NVX's Certiva...
BioCentury | Oct 11, 1999
Company News

North American Vaccine, Abbott deal

...Abbott terminated its 1996 agreement to market NVX's Certiva diphtheria, tetanus and acellular pertussis (DTaP) vaccine...
...distributing the vaccine to the private sector. NVX has received the entire $18 million of Certiva-related...
...million related to combination vaccines covered in the agreement. NVX also temporarily suspended production of Certiva...
BioCentury | Apr 5, 1999
Finance

1Q Market Review: Divergence of big & small

...binder from GelTex Pharmaceuticals Inc. (GELX, Waltham, Mass.) and Genzyme General (GENZ, Cambridge, Mass.); and Certiva...
BioCentury | Feb 8, 1999
Finance

Placebo pills?

...Noteworthy, A8). In November, NVX and Abbott's Ross Products division began U.S. sales of NVX's Certiva...
Items per page:
1 - 10 of 29